Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity





Published: October 2013 | Pages: 72 | Format: PDF

 Summary 

 GBI Research has released its research, Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity, which provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications. 

 Scope 

 

  •  Disease overview and treatment usage patterns 
  •  Market size and forecast for glaucoma and DES in APAC market from 2012 to 2019 
  •  Major marketed products for the indications types covered 
  •  In-depth pipeline analysis for glaucoma and DES 
  •  Key drivers and restraints that have had and are expected to have a significant impact upon the market 
  •  Key licensing and co-development agreements in the ophthalmology market 

 

 Reasons to buy 

 The report will enhance your decision-making capability by allowing you to - 

 

  •  Align your product portfolio to the markets with high growth potential 
  •  Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth 
  •  Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market 
  •  Develop key strategic initiatives based upon an understanding of key focus areas and leading companies 
  •  Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships 

 

 1 Table of Contents 

 1.1 List of Tables 

 1.2 List of Figures 

 2 Ophthalmology Therapeutics Market in Asia-Pacific – Introduction 

 2.1 Dry Eye Syndrome 

 2.1.1 Classification 

 2.1.2 Symptoms 

 2.1.3 Etiology 

 2.1.4 Pathophysiology 

 2.1.5 Diagnosis 

 2.1.6 Epidemiology 

 2.1.7 Prognosis 

 2.1.8 Treatment Options 

 2.2 Glaucoma 

 2.2.1 Classification 

 2.2.2 Symptoms 

 2.2.3 Etiology 

 2.2.4 Pathophysiology 

 2.2.5 Diagnosis 

 2.2.6 Epidemiology 

 2.2.7 Prognosis 

 2.2.8 Treatment Options 

 3 Ophthalmology Therapeutics Market in Asia-Pacific – Marketed Products (Global) 

 3.1 Dry Eye Syndrome 

 3.2 Glaucoma 

 3.3 Key Marketed Products 

 3.3.1 Restasis 

 3.3.2 Systane 

 3.3.3 Diquas 

 3.3.4 Mucosta 

 3.3.5 Hyalein 

 3.3.6 Lumigan 

 3.3.7 Alphagan/Alphagan P 

 4 Ophthalmology Therapeutics Market in Asia-Pacific – Pipeline Analysis 

 4.1 Dry Eye Syndrome Pipeline 

 4.1.1 Overall Pipeline 

 4.1.2 Pipeline Analysis by Molecule Type 

 4.1.3 Pipeline Analysis by Mechanism of Action 

 4.2 Glaucoma Pipeline 

 4.2.1 Overall Pipeline 

 4.2.2 Pipeline Analysis by Molecule Type 

 4.2.3 Pipeline Analysis by Mechanism of Action 

 4.3 Promising Drug Candidates in the Pipeline 

 4.3.1 CF-101 

 4.3.2 MIM-D3 

 4.3.3 SAR-1118 

 4.3.4 DE-111 

 5 Ophthalmology Therapeutics Market in Asia-Pacific – Market Forecast to 2018 

 5.1 APAC Market 

 5.1.1 Treatment Usage Patterns 

 5.1.2 Annual Cost of Therapy 

 5.1.3 Market Size 

 5.2 India 

 5.2.1 Treatment Usage Patterns 

 5.2.2 Annual Cost of Therapy 

 5.2.3 Market Size 

 5.3 Australia 

 5.3.1 Treatment Usage Patterns 

 5.3.2 Annual Cost of Therapy 

 5.3.3 Market Size 

 5.4 China 

 5.4.1 Treatment Usage Patterns 

 5.4.2 Annual Cost of Therapy 

 5.4.3 Market Size 

 5.5 Japan 

 5.5.1 Treatment Usage Patterns 

 5.5.2 Annual Cost of Therapy 

 5.5.3 Market Size 

 5.6 Drivers and Barriers 

 5.6.1 Drivers 

 5.6.2 Barriers 

 6 Ophthalmology Therapeutics Market in Asia-Pacific – Deals and Strategic Consolidations (Global) 

 6.1 Deals Analysis 

 6.2 Major Co-Development Deals 

 6.2.1 NicOx Signs Research Agreement with Pfizer 

 6.2.2 Acucela Enters into Co-Development Agreement with Otsuka Pharma for Rebamipide 

 6.2.3 Akorn Enters into Agreement with Azad Pharma 

 6.3 Major Licensing Deals 

 6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 

 6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 

 6.3.3 Asterand Enters into Licensing Agreement with Allergan 

 7 Ophthalmology Therapeutics Market in Asia-Pacific – Appendix 

 7.1 All Pipeline Drugs by Phase 

 7.1.1 Discovery 

 7.1.2 Preclinical 

 7.1.3 IND/CTA-filed 

 7.1.4 Phase I 

 7.1.5 Phase II 

 7.1.6 Phase III 

 7.1.7 Pre-registration 

 7.1.8 Undisclosed 

 7.2 Market Forecasts to 2019 

 7.2.1 APAC 

 7.2.2 Australia 

 7.2.3 China 

 7.2.4 India 

 7.2.5 Japan 

 7.3 Market Definitions 

 7.4 Abbreviations 

 7.5 Sources 

 7.6 Research Methodology 

 7.6.1 Coverage 

 7.6.2 Secondary Research 

 7.6.3 Primary Research 

 7.6.4 Therapeutic Landscape 

 7.6.5 Geographical Landscape 

 7.6.6 Pipeline Analysis 

 7.7 Expert Panel Validation 

 7.8 Contact Us 

 7.9 Disclaimer 

 1.1 List of Tables 

 Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 

 Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 

 Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 

 Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 

 Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 

 Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 

 Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 

 Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 

 Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 

 Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 

 Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 

 Table 12: Ophthalmology Therapeutics Market APAC, Dry Eye Syndrome, Market Forecast, 2012–2019 

 Table 13: Ophthalmology Therapeutics Market, APAC, Glaucoma, Market Forecast, 2012–2019 

 Table 14: Ophthalmology Therapeutics Market, Australia, Dry Eye Syndrome, Market Forecast, 2012–2019 

 Table 15: Ophthalmology Therapeutics Market, Australia, Glaucoma, Market Forecast, 2012–2019 

 Table 16: Ophthalmology Therapeutics Market, China, Dry Eye Syndrome, Market Forecast, 2012–2019 

 Table 17: Ophthalmology Therapeutics Market, China, Glaucoma, Market Forecast, 2012–2019 

 Table 18: Ophthalmology Therapeutics Market, India, Dry Eye Syndrome, Market Forecast, 2012–2019 

 Table 19: Ophthalmology Therapeutics Market, India, Glaucoma, Market Forecast, 2012–2019 

 Table 20: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 

 Table 21: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 

 1.2 List of Figures 

 Figure 1: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 

 Figure 2: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 

 Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 

 Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 

 Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 

 Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 

 Figure 7: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 

 Figure 8: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 

 Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 

 Figure 10: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 

 Figure 11: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 

 Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 

 Figure 13: Ophthalmology Therapeutics Market, APAC, Market Size ($m), 2012–2019 

 Figure 14: Ophthalmology Therapeutics Market, India, Market Size ($m), 2012–2019 

 Figure 15: Ophthalmology Therapeutics Market, Australia, Market Size ($m), 2012–2019 

 Figure 16: Ophthalmology Therapeutics Market, China, Market Size ($m), 2012–2019 

 Figure 17: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 

 Figure 18: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 

 Figure 19: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 

 Figure 20: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 

 Figure 21: GBI Research Market Forecasting Model